Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NCM · Healthcare · Biotechnology
$4.25
+2.41%
Closing price as of 2026-10-28 · Source: TEK2day Finance
Key Metrics
Market Cap
$82.2M
Shares Outstanding
19.3M
Exchange
NCM
Currency
USD
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (24.4M) | (22.0M) | (24.3M) | (36.2M) |
| Net Income | (23.3M) | (20.6M) | (23.0M) | (35.0M) |
| Diluted EPS | $-1.90 | $-1.25 | $-1.23 | $-1.81 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (34.8M) | (45.1M) | (48.7M) | (85.3M) |
| Net Income | (42.3M) | (44.6M) | (40.2M) | (78.5M) |
| Diluted EPS | $-10.15 | $-10.31 | $-3.68 | $-5.90 |